Samsung Biologics Expands Orders... Participates in BioProcess International

Exclusive Booth Operation at Exhibition Hall
Strengthening Business Networking and Partnerships

Samsung Biologics announced on the 21st that it participated in the global bio-industry conference, '2023 Bioprocess International (BPI),' to expand its order intake.

Samsung Biologics participated in the '2023 BioProcess International (BPI)' held in Boston, USA, from the 18th to the 21st (local time) to expand global orders. A view of the Samsung Biologics exclusive booth set up inside the BPI exhibition hall.
[Photo by Samsung Biologics]

Bioprocess International is a global bio-industry event that shares the latest technologies and discusses partnerships across all areas of biopharmaceutical development, production, and analysis. This year, it was held in Boston, USA, for four days from the 18th to the 21st (local time).

During the event, more than 200 companies from around the world set up exhibition booths, and over 2,700 global bio experts visited the exhibition hall. This BPI focused intensively on accelerating the commercialization of biopharmaceuticals and cell and gene therapies (CGT). Academic sessions were held in eight major fields, including culture purification processes, analytical technologies, and production strategies.

Samsung Biologics installed a standalone booth inside the exhibition hall during the event. Through a wall graphic, the booth introduced the world's largest production capacity of 604,000 liters and the competitiveness of its Contract Development Organization (CDO) platform. The expanded portfolio, including antibody-drug conjugates (ADC) and messenger ribonucleic acid (mRNA), was also showcased.

On one wall of the booth, the 'Customized CMC Solution' service package, launched last month to improve CDO efficiency, was introduced to attract customer orders. A separate space for client meetings and a lounge area for on-site customer support were also prepared to facilitate partnership discussions.

On the second day of the event, Janet Lee, Head of the Cell Line Development Group at Samsung Biologics, spoke in a session titled 'Maximizing Protein Expression through the S-CHOICE Cell Line Development Platform,' presenting the competitiveness of the contract development platform and business vision.

Additionally, Samsung Biologics participated as a sponsor of the event, installing banner advertisements in the main lobby and entrance pathways of the exhibition hall, while conducting digital poster presentations in a specially designated poster hall inside the venue.

Meanwhile, responding to high interest and continuous requests from global investors, Samsung Biologics was the only domestic pharmaceutical and bio company to participate in the 'CITIC CLSA Investor Forum' held in Hong Kong from the 11th to the 14th. This event, hosted by CLSA Securities, is Asia's largest investor conference where leading global investment institutions gather to discuss investments.